Marinus Pharmaceuticals
(NASDAQ) MRNS
Marinus Pharmaceuticals Financials at a Glance
Market Cap
N/A
Revenue (TTM)
$31.47M
Net Income (TTM)
$140.49M
EPS (TTM)
N/A
P/E Ratio
N/A
Dividend
N/A
Beta (Volatility)
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
MRNS News
MRNS: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Marinus Pharmaceuticals
Industry
Pharmaceuticals
Sector
Health CareEmployees
165
CEO
Scott N. Braunstein, MD
Website
www.marinuspharma.comHeadquarters
Radnor, PA 19087, US
MRNS Financials
Key Financial Metrics (TTM)
Gross Margin
94%
Operating Margin
-4%
Net Income Margin
-5%
Return on Equity
-2%
Return on Capital
-1%
Return on Assets
-83%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$29.05M
Operating Income
$131.49M
EBITDA
$125.50M
Operating Cash Flow
$118.00M
Capital Expenditure
$119.00K
Free Cash Flow
$118.12M
Cash & ST Invst.
$150.29M
Total Debt
$110.36M
Marinus Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$8.54M
+16.4%
Gross Profit
$7.83M
+13.7%
Gross Margin
91.64%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
165
N/A
Net Income
$24.23M
+26.5%
EBITDA
$21.08M
+26.1%
Quarterly Fundamentals
Net Cash
$13.81M
-113.5%
Accounts Receivable
$3.84M
-10.3%
Inventory
$6.72M
+145.5%
Long Term Debt
$41.71M
-36.6%
Short Term Debt
$14.28M
+69.9%
Return on Assets
-82.74%
N/A
Return on Invested Capital
-1.01%
N/A
Free Cash Flow
$20.57M
+18.6%
Operating Cash Flow
$19.45M
+22.7%